VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2021 | Optimizing outcomes for patients with VOD/SOS

Paul Richardson, MD, MSc, Dana-Farber Cancer Institute, Boston, MA, gives a presentation on the optimization of treatment for patients with veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). Dr Richardson outlines risk stratification based on risk factors including biomarkers and treatment with gemtuzumab ozogamicin, sirolimus or tacrolimus. Dr Richardson also outlines the use of defibrotide in the treatment of VOD/SOS, giving an overview of its mechanism of action and summarizing data from clinical trials. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter